Objective: To evaluate the prognostic value of high-sensitivity troponin T (hs-cTnT) in patients who present to General Practitioners (GPs) with non-acute chest pain. Design, setting and patients: A total of 625 patients who were referred by their GPs to a regional Rapid Access Chest Pain Clinic in Tayside, Scotland were consented and recruited. Diamond-Forrester pretest probability of coronary artery disease (CAD) was used to select patients with intermediate and highpretest probability. Hs-cTnT and B-type Natriuretic Peptide (BNP) were measured and final diagnosis recorded. Twelve-month follow-up for cardiac events and hospital admission data was collected. Sensitivity, specificity, positive predictive value and negative predictive value (NPV), for both prognosis and diagnosis, were produced using various pre-specified cut-off values for hs-cTnT and BNP.
Introduction
A new fifth-generation assay of highly sensitive troponin T (hs-cTnT) is able to quantify molecules of troponin in the microcapillary circulation and therefore has a detection level that is at least one order of magnitude lower than the cTnT assay in widespread use throughout the UK. 1 As a result, recent evidence has shown that the hs-cTnT assay is a more sensitive test for the diagnosis of myocardial infarction (MI) and acute coronary syndromes (ACS) compared to the widely used fourthgeneration assay (cTnT). [2] [3] [4] [5] [6] Hs-cTnT is also better able to risk stratify patients with acute MI. 7 This high-sensitivity assay has replaced the standard troponin T assay at many institutions, but its clinical utility is not fully defined in the different clinical setting of non-acute chest pain of uncertain origin with which general practitioners (GP) are often faced. Furthermore, clinical tests perform differently in different patient populations Rapid Access Chest Pain Clinics have been set up in the UK to address the large number of patients who present to their GP with non-acute chest pain of uncertain origin. Ultimately, less than half of such patients have a cardiac cause for their chest pain. 8 GPs are understandably anxious not to miss cardiac chest pain. We set out to determine if a single hs-cTnT at presentation provided any useful information to aid GPs' decisions on whom to refer to RACPC.
A troponin cut-off <14 ng/l represents the 99th centile for healthy subjects 3, 5 and higher levels indicate a degree of myocardial damage. However, lower levels of hs-cTnt between 1 and 14 ng/l may still be clinically useful as a prognostic marker in non-acute patients. Defining the role of highsensitivity troponin T in this large cohort could assist clinicians to better understand their cardiovascular risk and enable them to streamline healthcare delivery. This current study aimed to determine what role, if any, hs-cTnt, would play in the setting of non-acute chest pain of uncertain origin that present to general practice.
Another test that could have the potential to fulfil this role is B-Type Natriuretic Peptide (BNP). It is now established in the diagnosis of heart failure based on data from several well known trials, [9] [10] [11] but newer evidence also points to a role for BNP in diagnosing myocardial ischemia. This new role for BNP as an indicator of myocardial ischemia has recently been reviewed. 12 It is important to point out that this new use of BNP is seen at levels well below those used to diagnose LV systolic dysfunction (LVSD), i.e. 10-100 pg/ml (as opposed to >100 pg/ml). In fact, the ability of BNP to detect CAD in general had been confirmed in several recent studies.
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Methods
Patients attending the Rapid Access Chest Pain Clinic in Arbroath, Scotland were approached and consented for the study by a research nurse (G.M.). These clinics have been set up in the community to provide GPs with a referral option for patients who have non-acute chest pain. Numerous studies have shown such clinics to be cost-effective in the management of chest pain in the community. [19] [20] [21] [22] This study was conducted over 3 years from November 2005 to October 2008. All subjects gave written informed consent to participate in the study, which had prior approval by the Tayside Committee on Medical Research Ethics and was conducted in accordance with the Declaration of Helsinki.
We recruited 625 consecutive patients who were referred by their GP to a local RACPC. Demographic data and results of cardiac investigations were documented. We measured BNP by a near-patient test at the RACPC. Four milliliters of whole blood EDTA sample was taken for near patient-BNP (np-BNP) testing using the Biosite Õ Triage BNP fluorescence immunoassay test kit (Biosite Inc Õ , San Diego CA, USA). A further 5 ml of serum were centrifuged at 3000 rpm and stored at À608C. At the end of the study, the stored samples were analyzed for hs-cTnT using the Roche high-sensitivity troponin T assay utilizing the Elecsys 2010 system. The coefficient of variation (CV) at low-level readings for the assay as measured by in-house quality control measures was 3.4%. This is comparable to other recently published studies using the hs-cTnt assay 23 . The aim of the study was to observe the cohort based on an initial hs-cTnt rather than to use the measurement to guide management. The results of hs-cTnT analyses were not known to the clinician during the initial chest pain clinic visit and therefore did not influence clinical decision making by the physician.
Analyses were done in 579 patients with valid data as well as a subgroup of patients (n = 477) with intermediate or high-pre-test probability of coronary artery disease (CAD) using the Diamond and Forrester score. 24 A diagnosis of a cardiac cause for their chest pain was made based on a combination of clinical history and examination, which formed the clinical impression by the consulting cardiologist, and the results of a positive exercise tolerance test, coronary angiography or a positive troponin T (if the patient was admitted directly from the clinic). This, we would expect, represents 'real-world' clinical practice.
Twelve-month follow-up data for hospital admission, for cardiac chest pain, acute coronary syndrome, MI or cardiac death (hereafter referred to as 'cardiac events') were obtained from the patients' case notes and from their GP if this information was not available in the patients' case notes. The patients were also contacted at the 12-month point to confirm the follow-up data. All causes of death for patients who died within the 12-month follow-up period was obtained from death certificates either from the Registrar of Births and Deaths (Scotland) or the patients' medical records held at National Services Scotland (Aberdeen, Scotland). The authors had full access to the data and take full responsibility for its integrity. 2 in a study of hs-cTnT in the general population, hs-cTnT analyses were performed as an ordered categorical variable. Patients were divided to five diagnostic and prognostic cut-off levels at hs-cTnT 43 (lower limit of detection), <5, <10, <14 and >14 ng/l (>99th centile cut-off for healthy individuals). 3, 5, 6 Descriptive statistics and independent samples t-tests were carried out between the various hs-cTnT cut-offs. Analysis of variance (ANOVA) with Bonferroni correction was carried out to detect differences between the different groups. For nominal data, chi-squared tests were applied as appropriate. Diagnostic sensitivity, specificity, positive predictive value, negative predictive value (NPV) and receiver operating characteristic (ROC) were produced using various pre-specified cut-off values for BNP and hs-cTnT and the combination of the two tests.
Statistical analysis
Results Figure 1 provides a CONSORT diagram for participants in the study. A total of 625 patients were approached and consented for the study. Of them 579 samples were valid and analyzable. A total of 477 patients had either an intermediate or high pre-test probability of CAD. Baseline demographic data for all patients according to pre-specified cut-off levels are shown on Table 1 . There was no difference in past history of MI, current smokers, BMI, percent males, ASSIGN score, total cholesterol or HDL levels between all cohorts. Patients with hs-cTnT 414 ng/l had significantly lower mean BNP levels [36.64 (SD 45.82)] than patients with hs-cTnT> 14 ng/l [mean 102.37 (SD 90.36)] (P < 0.01). The lower limit of detection for the hs-cTnT assay was 3 ng/l. Among them, 265 patients (55.6%) had a hs-cTnT 43 ng/l. Patients with hs-cTnT43 ng/l were significantly younger and had less past history of hypertension than other cohorts. The previously reported 99th centile at 14 ng/l for healthy individuals 3,5 is used at our institution for a diagnostic cut-off value in ACS and MI. A total of 431 patients (90.4%) had a hs-cTnT of 414 ng/l. There were no cardiac deaths in the 12-month follow-up cohort further confirming that the cohort being studied has relatively low-risk cardiac chest pain. Future admission rates (false negative) using different hs-cTnt cut-off are shown on Table 2 .
Prognosis (overall cohort)
The utility of hs-cTnT and BNP as a predictor of 12-month admissions for cardiac events in all patients presenting to general practice with chest pain at 1-year follow-up is shown on important i.e. the ability to determine that patients who have tested negative truly do not have the condition tested for and therefore can be safely discharged. As a single test to determine if a patient would be admitted for cardiac chest pain in the following 12 months, hs-cTnT 14 ng/l provided the highest specificity (91.5%) with a good NPV (91.9%). BNP 10 ng/l had the highest NPV (94.4%). The combination of BNP and hs-cTnT at various cut-offs did not improve either specificity or NPV significantly.
Prognosis (intermediate and high-pre-test probability cohort)
The utility of hs-cTnT and BNP as prognostic rule-out tests in intermediate and high probability patients presenting to general practice with chest pain at 1-year follow-up is shown on Table 4 . As with the overall cohort, hs-cTnT 14 ng/l was a good test to negatively predict a further cardiac event in the following 12 months. A hs-cTnt cut-off provided the highest specificity (90%) with a good NPV (91.4%). BNP 10 ng/l had the highest NPV (94.3%). The combination of BNP and hs-cTnT at various cut-offs did not improve either specificity or NPV significantly (data not shown).
Diagnosis
Although assessment of the diagnostic ability of hs-cTnT was not the main aim of this study, this is reported here for completeness. A 'diagnosis' represents whether chest pain was diagnosed as cardiac in origin after the initial assessment and investigation at the RACPC. As expected, in the overall cohort, there was a significant difference between hs-cTnT levels in patients without diagnosed CAD [mean 7.11 (95% CI 5.3-8.9) vs. those diagnosed with CAD [mean 16.52 (95% CI 7.39-25.66)] (P = 0.001).
We found that a hs-cTnt value of 14 ng/l had the best specificity (92.1%) and a reasonable NPV (83.5%) i.e. at this level, it performed well at ruling out that the chest pain was of cardiac origin. BNP alone performed poorly at all cut-offs and the addition of BNP to any cut-off of troponin T worsened the specificity of the combined test.
Discussion
Our main finding is that a single negative hs-cTnT could provide useful reassurance to a GP that a patient referred to a RACPC would be significantly less likely to be admitted to hospital in the next 12 months with a cardiac cause for their chest pain. We did not find any significant differences between the overall cohort and the intermediate/ high-pretest probability cohort. It is hoped that GPs routinely calculate pre-test probabilities in clinical practice before referring patients who present with non-acute chest pain for further assessment. Therefore, we analyzed the subgroup of patients with intermediate and high pre-test probability of CAD using the Diamond-Forrester score separately because these would be the cohort that GPs would refer if they utilized a pre-test probability score as an initial screening tool as recommended by published guidelines 25 . It must be emphasized that patients with autonomic symptoms, classical crushing chest pain and very high background risk are referred directly to the Emergency Department rather than to an outpatient chest pain clinic. Therefore, the cohort that we studied represents a 'grey area' that often poses a diagnostic and prognostic challenge to GPs with regards to the cause and significance of the presenting chest pain. The question which we addressed was how a sensitive marker of cardiac necrosis (hs-cTnT) would perform alone, or in combination, with a marker of cardiac ischemia (BNP) with regards to subsequent 12-month admissions in patients with non-acute chest pain.
It must be emphasized that the findings of this study would not mean that GPs are to substitute clinical judgment on whether or not to refer patients to RACPC, with a blood test. It is intended to provide assurance that, should a single hs-cTnt be performed in either primary care or at presentation to RACPC, a level of <14 ng/l would indicate that, in conjunction with a negative clinical impression and/or investigations, that particular patient would be significantly less likely to be diagnosed with a cardiac cause for their for their chest pain in the following 12 months.
The role of lower levels of hs-cTnT which are undetectable using conventional fourth-generation assays in the prognosis of patients with ACS has been previously reported. 5, 26, 27 However, the prognostic role of these high sensitivity troponin assays in patients with stable angina is not certain. A recent study in a heterogeneous group of patients with stable angina found that levels of high-sensitivity cardiac Troponin I (hs-cTnI) was not helpful in distinguishing the etiology of the elevations or in predicting prognosis 28 whereas others have found that For combination cut-offs an either/or principle is used.
in patients with known CAD, hs-cTnT values were significantly associated with the incidence of cardiovascular death and heart failure but not with MI. It is even less clear in patients with vague, non-acute or atypical chest pain. There have been numerous studies showing that the proportion of these patients that actually have CAD is very low 8 and even in patients who have been given a negative diagnosis, there is dissatisfaction with the diagnosis they are given. 29 There are currently no published studies looking at the role of hs-cTnT in the large number of patients who present to their GPs everyday with often vague, non-acute chest pain. However, it must be noted that in our cohort, a significant subgroup (82%) had an intermediate or high-pretest probability of CAD, using the validated Diamond-Forrester score. 24 This highlights the need for a better tailored assessments of these patients.
This current study has shown that at the same diagnostic cut-off for ACS and MI (14 ng/l), hs-cTnT is also an indicator of subsequent 12-month admission for cardiac chest pain with a specificity of 91.5% and a NPV of 91.9%. Crucially, the addition of various cut-offs of BNP in a either/or combination with hs-cTnT did not improve specificity, despite a slight improvement in the NPV (Tables 3 and 4) . Using a hs-cTnT cut-off of 14 ng/l, the re-admission rate would be 7.8%. More stringent cut-offs would only slightly reduce the readmission rate (Table 2) . A combination cut-off of either hs-cTnT 5 ng/l or BNP 10 ng/l provided slightly lower specificity (90.7%) with a higher NPV (90.1%) than 14 ng/l hs-cTnT alone. However, this strategy will have to be balanced against the increased cost. On current platforms, both hs-cTnT and near patient BNP costs are comparable; therefore analysis of these in combination would double costs with only a slight improvement in performance.
There is extensive evidence on the diagnostic performance of hs-cTnT in MI and ACS, which is excellent 5 with 95% sensitivity, 80% specificity and 99% NPV. In our cohort of patients who present to general practice with often vague non-acute chest pain, we found that the diagnostic specificity (93.0%) and NPV (83.5%) in this cohort were comparable to previously published data in ACS and MI 5 but crucially the sensitivity (18.4%) was low in this cohort. This would suggest that in patients of non-acute chest pain, hs-cTnT should not be used as a diagnostic test.
Limitations
There are two main limitations to the current study. First, coronary angiography was not done in all patients, as this was a real-world study where cardiologists selected patients for further invasive investigations based on clinical judgment. In any case, even if all patients underwent coronary angiography, it is impossible to definitively prove that the cardiac chest pain was due to a particular lesion seen on angiography. The use of positive investigation results combined with the clinical opinion of a cardiologist is the best clinically applicable approximate to the diagnosis of cardiac disease. Second, there was the lack of a repeat sample. In ACS, patients presenting with chest pain have a second sample measured for hs-cTnT 6-9 h after the first, and a change (positive or negative) of 520% would indicate a positive result as shown in a recent study. 6 This may explain the low sensitivity seen in our study. The current NICE guidelines make reference to the Universal Definition of Myocardial Infarction (UDMI) statement, 30 which is based on the analytical imprecision of the assay as well as a rise and fall in the cardiac biomarker, preferably troponin, and that a significant change of >20% would represent reinfarction. Others suggest that a 50% change should be considered as significant, although this is usually in situations with a short time gap ($3 h) between specimens. There are varying opinions what constitutes a significant change: using a 20% increase will give greater sensitivity but will result in reduced specificity, whereas a 100% increase will reduce the sensitivity but increase the specificity. 31 However, in the setting of a RACPC, it would be cumbersome to repeat a second hs-cTnT sample 6 h after the first sample was taken.
Conclusion
We have found that hs-cTnT, at a level currently used in clinical practice as a diagnostic cut-off for MI and ACS, could also provide reassurance to clinicians that, in combination with a negative clinical assessment and/or investigations, a hs-cTnt 414 ng/l was a good indicator that the patient was very unlikely to have an admission for cardiac chest pain over the following 12 months. This information might help GPs and cardiologists in their decision making about the management of these patients.
